Chemotherapeutic drug combination

Patent metadata

Field	Value
Publication number	US-2016346325-A1
Application number	US-201515114854-A
Country	US
Kind code	A1
Filing date	Jan 14, 2015
Priority date	Jan 30, 2014
Publication date	Dec 1, 2016
Grant date	—

Abstract

The present invention relates to a chemotherapeutic drug combination containing heterodinuclear Cu (II)-Mn(II) complex. The objective of the present invention is to provide a drug combination, which will be actively used in chemotherapy, is anticarcinogenic and has no side effects, facilitates penetration into the cell, shows selectivity only for cancer cells and does not harm healthy cells, and is not toxic for the tissues and organs in the body, and which can prepared easily and provides a definitive and fast treatment.

First claim

1 . A chemotherapeutic drug combination comprising a combination of polynuclear Schiff base complex and pluronic.

2 . The chemotherapeutic drug combination according to claim 1 , wherein polynuclear Schiff base complex is heterodinuclear Cu(II)-Mn(II) complex.

3 . The chemotherapeutic drug combination according to claim 1 , wherein phironic is selected from at least one of F68, F127, P106, P407, P85, P123.

4 . The chemotherapeutic drug combination according to claim 3 , which is effective in cancer treatment.

5 . The chemotherapeutic drug combination comprising a therapeutically effective amount of polynuclear heterodinuclear Cu (II)-Mn(II) complex.

6 . The chemotherapeutic drug combination according to claim 5 , which is therapeutic particularly in prostate cancer, and in cancer types such as AIDS-related cancer types, breast cancer and derivatives thereof, gastrointestinal tract-related cancer types, endocrine and neuroendocrine cancers, eye cancer, genitourinary system cancer types, gynecological cancer types, prostate cancer and derivatives thereof, germ cell cancer, head and neck cancer, hematologic cancer and leukemia, musculoskeletal system cancers, neurological cancers, respiratory system and thoracic cancers, skin cancer, cancers of unknown origin, acute lymphoblastic leukemia, acute myeloid leukemia cancer types observed in childhood, breast, cervical, endometrial, ovarian, uterus, vagnial, vulval cancer types observed in women.

7 . The chemotherapeutic drug combination according to claim 6 , which is therapeutic in cancer types of astrocytoma, glioma, lung cancer, hepatoma, colon cancer, osteoid cancer, pancreatic cancer, skin cancer, cervical cancer : , melanoma, uterine cancer, ovarian cancer, rectal cancer, gastric cancer, anal cancer, colon carcinoma, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, Hodgkin's disease, esophageal cancer, small bowel cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penial cancer, prostate cancer, urinary bladder cancer, kidney or ureter cancer, renal cell carcinoma, pelvic carcinoma, central nervous system (CNS) tumor,. primary CNS lymphoma, spinal cord tumor and hypophysis adenoma.

Assignees

• Univ Yeditepe

Inventors

• Sahin Fikrettin
• Dogan Aysegül
• Demirci Selami
• Basak Nese
• DEDE Bulent

Classifications

• A61K33/32

  Manganese; Compounds thereof · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C08L71/02

  Polyalkylene oxides · CPC title

• A61K33/34 Primary

  Copper; Compounds thereof · CPC title

• A61P35/00

  Antineoplastic agents · CPC title